Matthew J. Koster

TL;DR: Recent data suggest that biologic therapies, such as tocilizumab, may be effective and safe steroid-sparing options for patients with GCA, however, data specifically evaluating the management of LV-GCA are limited.

TL;DR: Females and patients with hypertension or diabetes at GCA diagnosis have more relapses during follow-up and patients treated with an initial oral prednisone dose >40 mg/day achieved earlier prednis one discontinuation.

TL;DR: This consensus statement represents a joint document from a multidisciplinary group of physicians at Mayo Clinic who specialize in the management of adult histiocytic neoplasms and consists of evidence- and consensus-based recommendations on when to suspect these neoplasm and what tests to order for the diagnosis and initial evaluation.

TL;DR: Abatacept and ustekinumab are promising targets for therapy in LVV but further investigation is needed before routine use is considered, and utility in newly diagnosed immunosuppressive-naïve patients is less well established.

TL;DR: Heiblig et al. as discussed by the authors performed a retrospective analysis of 30 patients with VEXAS syndrome treated with different Janus kinase (JAK) inhibitors, finding encouraging evidence supporting the use of the JAK1/2 inhibitor ruxolitinib with clinical remissions and reductions in steroid use seen in the majority of patients.